title: Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells.
abstract: Postulated cytoprotective action of (-)-deprenyl (D), (-)-desmethyl-deprenyl (DD) and (-)-deprenyl-N-oxide (DNO) on L-buthionine-(S,R)-sulfoximine (BSO) toxicity was investigated using in vitro cultures of serum-deprived A-2058 melanoma cells. BSO (10 microM/l) decreased viable cell number and mitotic rate, while increased the apoptotic index. D and both of its metabolites, given together with BSO in the concentration of 50 microM/l, mitigated cell loss and decreased the apoptotic ratio. DD was the most effective compound in decreasing apoptotic activity, while DNO stabilized the cell number on control level and increasing the ratio of mitotic cells above the only serum-deprived control. Surveillance on mitochondrial membrane stability and antioxidant properties may play an important role in these processes.
authors.affiliation: 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
authors.forename: B
authors.initials: B
authors.lastname: Szende
authors.forename: G
authors.initials: G
authors.lastname: Barna
authors.forename: Kálmán
authors.initials: K
authors.lastname: Magyar
mesh_terms: D000662:Amphetamines / Q000494:pharmacology*; D019328:Buthionine Sulfoximine / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D019610:Cytoprotection / Q000187:drug effects*; D004347:Drug Interactions; D005434:Flow Cytometry / Q000379:methods; D005978:Glutathione / Q000494:pharmacology*; D006801:Humans; D008545:Melanoma / Q000473:pathology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents; D012642:Selegiline / Q000031:analogs & derivatives* / Q000494:pharmacology; D044967:Serum / Q000378:metabolism
chemical_list: D000662:Amphetamines; D008996:Monoamine Oxidase Inhibitors; D011838:Radiation-Sensitizing Agents; C484174:deprenyl-N-oxide; D012642:Selegiline; D019328:Buthionine Sulfoximine; C017861:desmethylselegiline; D005978:Glutathione
references.citation: J Pharmacol Exp Ther. 2002 May;301(2):753-64
references.pmid: 11961082
references.citation: J Neurosci Res. 1994 Feb 1;37(2):278-86
references.pmid: 8060389
references.citation: Mech Ageing Dev. 2002 Apr 30;123(8):1081-6
references.pmid: 12044957
references.citation: J Neural Transm (Vienna). 2001;108(1):25-33
references.pmid: 11261744
references.citation: J Neural Transm Suppl. 2007;(72):165-73
references.pmid: 17982891
references.citation: J Neurochem. 1994 Oct;63(4):1572-5
references.pmid: 7931312
references.citation: Anal Biochem. 1994 May 1;218(2):314-9
references.pmid: 8074286
references.citation: Br J Clin Pharmacol. 1978 Dec;6(6):542-4
references.pmid: 728327
references.citation: J Pharmacol Exp Ther. 1998 Feb;284(2):700-6
references.pmid: 9454817
references.citation: Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1913-7
references.pmid: 2000395
references.citation: Ann N Y Acad Sci. 2001 Jun;939:450-8
references.pmid: 11462801
references.citation: Life Sci. 1994;54(14):975-81
references.pmid: 8139387
references.citation: Neurotoxicology. 2004 Jan;25(1-2):233-42
references.pmid: 14697898
references.citation: Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9360-4
references.pmid: 1681551
references.citation: Neurology. 1996 Dec;47(6 Suppl 3):S171-83
references.pmid: 8959986
references.citation: J Pharmacol Exp Ther. 1977 Jan;200(1):25-32
references.pmid: 13201
references.citation: Curr Med Chem. 2004 Aug;11(15):2017-31
references.pmid: 15279565
references.citation: Pharmacol Ther. 1991;51(2):155-94
references.pmid: 1784629
references.citation: Electrophoresis. 2004 Aug;25(16):2866-75
references.pmid: 15352021